Chicago-based Blue Cross Blue Shield Association issued a positive assessment of Seattle-based NanoString's Prosigna Breast Cancer assay.
The positive BCBS Association Evidence Street assessment aligns with updated American Society of Clinical Oncology guidelines, which recommend using Prosigna to inform decisions on adjuvant systemic therapy for patients with early-stage breast cancer. The positive Evidence Street assessment is based on clinical and scientific evidence of improved health outcomes.
While Evidence Street does not determine local health plan policies, its review is a step toward health insurance providers in the BCBS affiliate network covering Prosigna.